RGEN News and Press, Repligen Corporation From 08/02/23

– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corpo...

2023-08-01 13:09:25 ET Repligen ( NASDAQ: RGEN ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is $0.48 (-47.3% Y/Y) and the consensus Revenue Estimate is $165.92M (-20.1% Y/Y). Over the last 2 yea...

2023-07-30 11:23:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Discovery Fund® (the Fund) appreciated 3.58% (Institutional Shares) in the ...

2023-07-25 07:30:47 ET Despite posting better than expected financials for Q2 2023, Danaher Corporation ( NYSE: DHR ) slipped ~5% pre-market Tuesday as the U.S. life sciences company lowered its full-year outlook amid falling COVID-related revenue. Danaher’s ( DHR ...

2023-07-21 11:43:42 ET Sartorius AG ( OTCPK:SARTF ) traded sharply higher on Friday, rallying the shares of its U.S. peers, after the German life sciences company posted its Q2 2023 results, indicating a gradual recovery following a post-pandemic contraction in demand. Notable gaine...

2023-07-20 13:08:32 ET Wells Fargo launched its coverage of Repligen Corporation ( NASDAQ: RGEN ) with an Overweight rating and a $185 price target on Thursday, noting that the life sciences company reflects overly negative investor concerns over its near-term headwinds. The ana...

WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2023 financial results on Wednesday, August 2, 2023. The Company will issue a press release before the market opens and will host a conference call ...

2023-07-18 11:35:14 ET Summary Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use products for biopharma manufacturing. The company is ex...

2023-06-28 16:10:16 ET Summary With growth prospects, ongoing deleveraging and margin expansion efforts, acquisition value realization and 85% recurring revenue mix, Avantor is well positioned to take advantage of the secular life science uptrend. Avantor faces near-term challenge...

2023-06-16 17:39:00 ET Gainers: Kezar Life Sciences ( NASDAQ: KZR ) +6% . Telos Corporation ( TLS ) +4% . Dyne Therapeutics ( DYN ) +4% . Recursion Pharmaceuticals ( RXRX ) +4% . Berry Corporation ( BRY ) +4% . Losers: ...